Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5774846 | 1.00 | MAPT (0.43) | MAPTNPC1RAB9AHPGDHTT | |
| SCHEMBL533848 | 0.84 | MAPT (0.44) | MAPTNPC1RAB9AHPGDHTT | |
| SCHEMBL17434732 | 0.84 | MAPT (0.44) | MAPTNPC1RAB9AHPGDHTT | |
| SCHEMBL533849 | 0.84 | MAPT (0.44) | MAPTNPC1RAB9AHPGDHTT | |
| Hydrochloric Acid SCHEMBL28407169 | 0.82 | MAPT (0.43) | MAPTNPC1RAB9AHPGDHTT | |
| SCHEMBL1968880 | 0.79 | NFE2L2 (0.48) | MAPTNPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL5805553 | 0.79 | TSHR (0.54) | MAPTNPC1RAB9AHPGDHTT | |
| SCHEMBL2924111 | 0.79 | NFE2L2 (0.48) | MAPTNPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL30778025 | 0.79 | TSHR (0.54) | MAPTNPC1RAB9AHPGDHTT | |
| SCHEMBL1968882 | 0.79 | NFE2L2 (0.48) | MAPTNPC1RAB9ASMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160030321-A1 | CALCIUM SEQUESTRATION COMPOSITIONS AND METHODS OF TREATING SKIN PIGMENTATION DISORDERS AND CONDITIONS | NEOCUITIS S A (CH) | 2016-02-04 | — | — | US | disclosed |
| EP-1224189-B1 | CONDENSED DIHYDROQUINOLINONE DERIVATIVES FOR INHIBITING MRP1 | LILLY CO ELI (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20040077675-A1 | Compounds and methods for inhibiting MRP1 | BONJOUKLIAN ROSANNE (US) | 2004-04-22 | — | — | US | disclosed |
| US-6670373-B1 | Inhibiting resistant neoplasms where the resistance is conferred by multidrug resistance protein; N-3,4,5-trimethoxyphenyl-3-(3-azidomethyl-isoxazolo(4,5-c) -1,2-dihydro-6-chloro-quinolin-2-on-1-yl)phenylacetamide | ELI LILLY AND COMPANY | 2003-12-30 | — | — | US | disclosed |
| EP-1224189-A2 | CONDENSED DIHYDROQUINOLINONE DERIVATIVES FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001027116-A2 | CONDENSED DIHYDROQUINOLINONE DERIVATIVES FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160030321-A1 | CALCIUM SEQUESTRATION COMPOSITIONS AND METHODS OF TREATING SKIN PIGMENTATION DISORDERS AND CONDITIONS | S100A4, TYR, CACYBP | MAPT 921/4885NPC1 840/4885RAB9A 537/4885 |
| US-20040077675-A1 | Compounds and methods for inhibiting MRP1 | ABCC1, ABCB1, ABCB11 | MAPT 4342/4885NPC1 17/4885RAB9A 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.